AI English summary of an SEC filing — figures as filed
Edwards Lifesciences EWThe company said net sales for the quarter ended June 30, 2025 rose to $1.53 billion, up 11.9% from a year earlier, and grew 10.6% on an adjusted basis.
Key points
AI summaryThe company said net sales for the quarter ended June 30, 2025 rose to $1.53 billion, up 11.9% from a year earlier, and grew 10.6% on an adjusted basis.
Edwards said TAVR sales for Q2 rose 8.9% from a year earlier to $1.1 billion (7.8% on a constant currency basis), and TMTT sales rose 61.9% to $134.5 million.
The company said its gross profit margin for Q2 was 77.5%, below 79.9% a year earlier, and cited additional manufacturing expenses tied to the expansion of new therapies and foreign exchange as the drivers of the change. Diluted earnings per share, including both continuing and discontinued operations, were $0.56.
The company raised its full-year sales growth outlook to 9 to 10% from 8 to 10%, with sales of $5.9 billion to $6.1 billion. It said it expects adjusted EPS to be at the high end of its original range of $2.40 to $2.50.
Summary
AI-writtenAnalysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.
Edwards Q2 sales hit $1.53 billion, up 11.9% year over year
The company said net sales for the quarter ended June 30, 2025 rose to $1.53 billion, up 11.9% from a year earlier, and grew 10.6% on an adjusted basis.
Source · Based on the filing body and exhibits
TAVR sales up 8.9%, TMTT sales hit $134.5 million
Edwards said TAVR sales for Q2 rose 8.9% from a year earlier to $1.1 billion (7.8% on a constant currency basis), and TMTT sales rose 61.9% to $134.5 million.
Source · Based on the filing body and exhibits
Gross margin at 77.5% in Q2, diluted EPS $0.56
The company said its gross profit margin for Q2 was 77.5%, below 79.9% a year earlier, and cited additional manufacturing expenses tied to the expansion of new therapies and foreign exchange as the drivers of the change. Diluted earnings per share, including both continuing and discontinued operations, were $0.56.
Source · Based on the filing body and exhibits
Edwards raises 2025 full-year sales growth outlook
The company raised its full-year sales growth outlook to 9 to 10% from 8 to 10%, with sales of $5.9 billion to $6.1 billion. It said it expects adjusted EPS to be at the high end of its original range of $2.40 to $2.50.
Source · Based on the filing body and exhibits
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…